

# immune profiling

WORLD CONGRESS 2016

11 – 12 October, 2016

Fairmont Rey Juan Carlos Barcelona, Spain

Learn. Discover. Network.

Co-located with



Created by



Part of



#wvceu

[terrapiinn.com/immune16](http://terrapiinn.com/immune16)

# New immune profiling technology is changing the whole industry

---

With newer and more advanced immune profiling technologies, we are getting to understand the human immune system more and more. From infection, vaccination to how disease or pathogens alters immune cell repertoires and their functional activities. This congress brings together experts to discuss how profiling of the immune system using high throughput technologies, can aid therapeutic design and treatment strategies in infectious and non-infectious diseases.

**Join us on the 11 – 12th October where we will cover:**

## **CHARACTERISATION OF THE IMMUNE RESPONSE**

- ◆ Understand how leading experts are gaining a better understanding of the disease process and predicting the onset of disease through effective characterisation of the immune response. Learn from case studies covering topics from categorising T-cell diversity, using biosystems approaches to define immune parameters, to analysing high-throughput transcriptomic and metabolic profiles for clinically useful biosignatures.

## **BIOMARKERS AND SURROGATE MARKERS OF VACCINE EFFICACY AND SAFETY**

From surrogate markers to predictive biomarkers of vaccine efficacy, attend these sessions to learn how realistic it is to enhance blood markers beyond serum antibodies. Examples will include specific systems used that have helped integrate the innate and adaptive immunity in the development of vaccines in the market.

## **IMMUNOSEQUENCING AND HIGH THROUGHPUT ANALYSIS**

Using high-throughput analyses, such as next generation sequencing, single cell technologies, transcriptomic and metabolic profiling to develop clinically useful biosignatures. Engage with experts in how they have been combining high-throughput sequencing and bioinformatics to profile T-cell and B-cells.

## **IMMUNOTHERAPY AND PROFILING IN CANCER**

Whether you are involved in check point inhibitors, neoantigens, adoptive T-cells therapies, CAR T-cells, oncolytic viruses or combinational methods – we have all the most innovative immunotherapy approaches covered. Hear from MSD, Aduro Biotech, Adaptimmune, Inserm Laboratory, Weizmann Institute of Science, Precision Biologics, Inc. and many more.

For more information visit [www.terrapinn.com/immune16](http://www.terrapinn.com/immune16)

"The WVC provides an excellent opportunity to combine the latest scientific information with the ability to provide practical solutions to client's clinical development and commercial manufacturing needs."

**IDT BIOLOGIKA**



# 2016 Agenda Overview

| DAY 1                            | DAY 2                                      | DAY 3                                      |
|----------------------------------|--------------------------------------------|--------------------------------------------|
| Vaccines                         | Vaccines<br>Immune Profiling<br>Veterinary | Vaccines<br>Immune Profiling<br>Veterinary |
| Break                            | Break                                      | Break                                      |
| Vaccines<br>Veterinary Workshops | Vaccines<br>Immune Profiling<br>Veterinary | Vaccines<br>Immune Profiling<br>Veterinary |



For full details and to book visit [terrapinn.com/immune16](http://terrapinn.com/immune16)

# Co-Located with



Back for the 17th year, the World Vaccine Congress is the place where the global vaccine industry meet to discuss commercial and scientific issues around regulation, strategy, manufacturing and clinical trials, as well as respiratory, cancer, and emerging diseases. Growing year on year, experience new speakers, more content and fantastic networking opportunities with over 450 total attendees! Join us on the 10 – 12 October in Barcelona where you can tailor your 3 days with us on the following agenda themes:



## **BIOPROCESSING, DELIVERY AND MANUFACTURING**

Optimize early formulation through to clinical manufacturing, by embracing new techniques and technologies.

## **INFLUENZA AND RESPIRATORY**

Find ways to improve development of universal influenza, RSV, MERS and Pneumococcal vaccines.



## **THERAPEUTIC**

From new adjuvant technologies to novel immunotherapies, better understand the latest developments in the fast-evolving landscape whether you are interested in cancer and immunotherapy, allergy or chronic infectious diseases.



## **EMERGING AND RE-EMERGING DISEASES**

Understand the opportunities for your business in reacting to global threats like malaria, dengue and Ebola.



## **PRE-CLINICAL VALIDATION TO CLINICAL TRIALS**

Assess how to improve your clinical trial performance, from developing novel immunological assays to creating clinical efficacy.



## **NEW VACCINE TECHNOLOGY**

From RNA to nanotechnology, hear from the most promising new biotechs, showcasing their innovative platforms and potential to the market.



For more information visit [terrapinn.com/vaccine16](http://terrapinn.com/vaccine16)

# Co-Located with

---



## Science, strategy and partnerships for the veterinary vaccine sector

A two day event with a pre-event workshop where the global animal health industry meets to discuss scientific, regulatory and commercial issues from new innovative vaccine technologies to emerging disease.

### **NEW VACCINE TECHNOLOGY AND PLATFORMS**

Focused on R&D innovations, this congress will update you of the progression made in veterinary vaccine R&D and vaccine development challenges when developing vaccines against viral, bacterial and parasitic diseases within a variety of animal species. From modified live virus vaccines, DNA vaccines, subunit marker vaccines to novel adjuvanted vaccines, this congress brings all innovation together in one place.

### **INDUSTRY INSIGHTS AND MARKET TRENDS**

Bridge the gap between animal and human health with a one health approach to control emerging diseases in a changing world. Hear from regulators who can advise you on what they are looking for when assessing new platforms for registration.

### **DEVELOPING AND FORMULATING NEW VACCINES**

From novel combination adjuvants for veterinary vaccines to making vaccines more affordable, meet experts who can delve into process improvements approaches when developing new vaccines.

### **ANTIMICROBIAL RESISTANCE AND EMERGING DISEASES**

Expect the unexpected, explore the opportunities and challenges associated with emerging infectious diseases including African swine fever, avian influenza and Rift Valley Fever. Find out how the industry is working together to find alternative routes (vaccines) to slow down the rise of antimicrobial resistance.

### **PRE-CONGRESS WORKSHOP: FROM AGENT IDENTIFICATION TO VACCINE SUPPLY**

Find out how to tackle the problems associated with identification of new threats and the turnaround time to producing vaccines. Discuss how the industry can readjust the risk assessment when responding to a new outbreak.



For more information visit [terrapinn.com/vetvaccine16](http://terrapinn.com/vetvaccine16)

9:00

**Chair's opening remarks**

## CHARACTERISATION OF THE IMMUNE RESPONSE

9:10

### The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis

- Using high-throughput analyses, such as transcriptomic and metabolic profiling to develop clinically useful biosignatures
- Gaining a better understanding of the disease process and predict onset of disease
- Biomarkers based on cytokine composition provide important insights into the basic biological principles of TB and give an opportunity to reliably distinguish TB patients from healthy individuals



**Prof Stefan Kaufmann**, Founding Director and Managing Director, **Max Planck Institute for Infection Biology**

9:40

### Analysis of the immune system during HIV infection

- Cellular immunity to HIV
- Using biosystems approaches to define immune parameters of HIV control
- Identifying predictors of vaccination outcome



**Dr Christian Brander**, Research Professor, IrsiCaixa & Scientific Director, **HIVACAT**

10:10

### Optimized immune profiling by understanding T-cell and B-cell repertoires during cancer

- Categorising T-cell diversity to cancer and disease
- A high-throughput method for sequencing and quantification of rearranged antigen receptors on T- and B-cells
- Functional genomics and genetics

10:40

Morning networking break

## BIOMARKERS AND SURROGATE MARKERS OF VACCINE EFFICACY AND SAFETY

11:40

### Unique Ig-seq approach for profiling the immune response after vaccination or disease

- Integration of next generation sequencing (NGS) and proteomics for the analysis of serum antibody repertoires
- The approach reveals the nature and dynamics of the serological response to vaccination with direct implications for vaccine design and evaluation
- Demonstrating a case study and future applications of this approach




**Dr Yariv Wine**, Head, laboratory for systems immunology, Dpt of Molecular Microbiology and Biotechnology, **Tel Aviv University**

12:10

### Skin immunity for vaccination using omics to better describe the innate immunity and to predict the adaptive immunity

**Dr Behazine Combadiere**, Director of Research DR2, **INSERM**



12:40

### Systems integration of innate and adaptive immunity: Implications for vaccine development

- Using computational tools to predict adaptive immunity
- Examples from RTSS malaria vaccine with GSK
- Finding other related pathways to test immunogenicity
- Hypothesise activities of adjuvants and biomarkers



**Dr Daniel Zak**, Assistant Professor, **The Center for Infectious Disease Research**

13:10

Networking Lunch & Poster Session

14:45

## Signatures and ink spots of vaccine induced responses

- From surrogate markers to predictive biomarkers of vaccine efficacy
- How realistic is it to enhance the blood markers beyond serum antibody?

**Dr Ali Harandi**, Associate Professor, Lab head, **University of Gothenburg**



## IMMUNOSEQUENCING AND HIGH THROUGHPUT ANALYSIS

15:15

## Rapidly screening a novel affinity scaffold library for PD-L1 Inhibitors

- High throughput protein expression capabilities
- Identifying multiple clones that inhibit PD-L1/PD1 interaction enabling further investigation of these as biotherapeutics leads

15:45

## Immunosequencing: Combining high-throughput sequencing and bioinformatics to profile T-cell and B-cells

- Translating immunosequencing discoveries into clinical diagnostics and therapeutic development
- Screening diverse targets, including soluble and complex membrane proteins from natural immune repertoires

16:15

Afternoon break

16:45

## Single-cell technologies: Validating discoveries and translating them into clinically useful diagnostic assays

- Enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen

17:15

## Utilising next generation sequencing for fast and accurate processing of sequencing data from T- and B- cell receptor libraries

- How has next-generation sequencing revolutionized the characterization of human immune responses?
- Identifying immunogenic mutations – Will these need to be patient specific to get meaningful antigens?

17:45

## Developing novel antibody immunotherapies that help the immune system attack diseased cells

- Studying rare immune cells at high resolution
- Measuring drug effects in a patient-specific, disease-specific manner
- Understanding broadly how immunotherapy works in humans, based on its ability to evaluate the function of critical rare immune cells in human clinical samples

18:15

Chair's closing remarks and close of day two followed by **Meet & Greet with key speakers**



9:05

Chair's opening remarks

## IMMUNO-ONCOLOGY APPROACHES

9:10

### Discussing the role of checkpoint inhibitors in the context of a broader immuno-oncology strategy

- Treating cancer by targeted activation of the immune system
- Dissecting antigen-specific T cell immunity in human cancer
- Reviewing toxicity profiles of checkpoint blockade and dual checkpoint blockade
- Patient selection on PDL-1 and 2 status
- Use of novel biomarkers and exciting combinations

**Dr Roy Baynes**, Senior Vice President Global Clinical Development, **MSD**



9:40

### Identifying solutions to improve the efficacy of PD-1 and CTLA-4

- Disabling the function of immune checkpoint molecules can unlock T-cell immunity against cancer
- Explaining possible causes of resistance that is essentially unexplained

10:10

### Next generation of immune checkpoint inhibitors

- Lessons learnt from regulatory challenges encountered in the development of checkpoint inhibitor immunotherapy
- Investigate strategies to validate novel checkpoint pathways and the potential of novel targets and combination with active immunization
- Impact on the future of the immune checkpoint inhibitor field

10:40

Morning networking break

11:30

### Insights from *Listeria monocytogenes* for the development of vector- and small molecule-based cancer immunotherapy strategies

- Modulating the tumour microenvironment and priming for tumour-specific immunity
- Inducing a systemic pro-inflammatory cytokine profile and facilitating immune recognition
- Evaluation of the impact of CRS-207/GVAX in combination with PD-1 blockade on survival in patients with metastatic pancreatic cancer

**Dr Thomas W. Dubensky**, Chief Scientific Officer, **Aduro Biotech**



12:00

### Enhancing the affinity of TCR engineered T-cells to tackle cancer

- Strengthening natural patient T-cell responses
- Targeting the NY-ESO cancer antigen
- Demonstrating efficacy and tolerability in Phase I/II trials in solid tumours and in hematologic cancer types

**Dr James Noble**, Chief Executive Officer, **Adaptimmune**



12:30

Networking Lunch

13:30

### Immunoscore®: An innovative combination of immunohistochemistry and digital pathology-based scoring

- Assessing multiple immune-related biomarkers currently under investigation
- Promising candidates for predicting patient response to immuno-oncology treatments in several solid tumours

**Dr Jerome Galon**, Research Director, **Chief, Inserm Laboratory**



14:00

### Next generation CAR Technology: Amplifying the immune response within the tumour microenvironment

- Using CAR T-cell therapy for optimal anti-cancer treatment
- Future challenges for the CAR T-cell approach and combinations with other cancer treatments and vaccines

**Prof Zelig Eshhar**, Professor, Chemical & Cellular Immunology, **Weizmann Institute of Science**



14:30

### Promising Phase II results in treatment of chemotherapy refractory colorectal and pancreatic patients in monotherapy clinical trial: A patient to lab approach

- Support and plans for Phase III trials
- Identifying various combination therapies and immune correlates
- Application's with new technologies including antibody drug conjugates (ADC), CAR T-cell, Bi-specific t-cell engagers (BiTEs) antibody

**Dr Philip M. Arlen**, President & Chief Executive Officer, **Precision Biologics, Inc.**



15:00

### Oncolytic viruses: a new class of immunotherapy drugs

- Promoting anti-tumour responses through a dual mechanism of action that is dependent on selective tumour cell killing and the induction of systemic anti-tumour immunity
- Unique challenges in the development of oncolytic viruses as a new class of drugs for the treatment of cancer

**Dr Ronald Herbst**, VP of Oncology Research, **Medimmune**



15:30

Chair's closing remarks and close of congress

PLENARY SESSION

8:50

Chair's opening remarks

9:50

Plenary Discussion: The threat of the Zika virus – What have we learnt from the Ebola crisis?

- What do we know about the pathogenesis of Zika virus infection?
- What is the quickest path to a safe and effective vaccine?
- What is the response regulatory authorities to vaccine development?
- Will a live virus vaccine be safe enough to vaccinate pregnant women? How will governmental agencies and NGO respond to the Zika threat?
- What financial assistance can be expected?



**Dr Line Matthiessen**, Head of Unit, Infectious Diseases, Directorate General for Research and Innovation, **European Commission**



**Dr Cristina Cassetti**, Deputy Chief, Virology Branch Division of Microbiology and Infectious Diseases, **National Institute of Allergy and Infectious Diseases, NIH**



**Dr Nicholas Jackson**, Vice President, Global Head of Research, **Sanofi Pasteur**



**Prof Leda Castilho**, Professor, **Universidade Federal do Rio de Janeiro**



**Dr Elliot Parks**, President & CEO, **Hawaii Biotech Inc.**

9:40

Providing RSV protection to pre-infants, elderly and maternal patients

- Overview of current RSV vaccine candidates
- Understanding RSV epidemiology and pathogenesis
- Challenges in providing effective and continuous immunity

**Dr Jerald Sadoff**, Senior Advisor to CEO, **Janssen Infectious Diseases and Vaccines**



10:10

How are advances in technology and immunotherapy changing the landscape for non-infectious diseases and therapeutic vaccines?

- The future of combination cancer immunotherapies with vaccines, checkpoint inhibitors, neoantigens and oncolytic viruses
- Cancer therapies are all heading to combinational approaches but how do we fine tune what should be combined and in what order?
- How will combinational approaches reduce side effects and replace conventional treatments including chemotherapy?

**Dr Karin Jooss**, & CSO, **Gritstone Oncology**



10:40

Networking lunch

11:40

RESPIRATORY VACCINES TRACK

Chair's opening remarks

THERAPEUTIC VACCINES TRACK

Chair's opening remarks

**Dr Michael G. Hanna, Jr.**, Founder & Chairman Emeritus, **Vaccinogen, Inc.**

EMERGING & RE-EMERGING DISEASES

Chair's opening remarks

11:45

INFLUENZA VACCINES

Presenting a novel universal influenza vaccine: Enhancing the standard of care

**Dr Harry Kleanthous**, Ass. Vice President, Head Discovery Research North America, **Sanofi Pasteur**

CANCER AND IMMUNOTHERAPY VACCINES

The paradoxes and consequences of tumour genomic heterogeneity

**Dr Michael G. Hanna, Jr.**, Founder & Chairman Emeritus, **Vaccinogen, Inc.**

PLATFORM TECHNOLOGIES TO EMERGING PATHOGENS

Being prepared: Promising new platform technologies applicable for vaccine development against emerging pathogens

**Prof Sarah Gilbert**, Professor of Vaccinology, Jenner Institute, **University of Oxford**

|       |                                                                                                                                                                                            |                                                                                                                                                                                                                             |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12:15 | <b>Advances and prospects for universal and broadly cross-reactive vaccines: Are we getting any closer?</b><br><b>Andrew Allen</b> , CEO & Co-Founder, <b>Gritstone Oncology</b>           | <b>The importance of neoantigens selection in cancer immunotherapy</b><br><b>Dr Jayanthi Wolf</b> , Director, Regulatory Affairs, <b>MSD</b>                                                                                |
| 12:45 | <b>High titre neutralizing antibodies to influenza after oral tablet immunization: A phase 1, randomized, placebo-controlled trial</b><br><b>Dr Sean Tucker</b> , CSO, <b>Vaxart, Inc.</b> | <b>Ph1 results of a new checkpoint inhibitor vaccine against lung and melanoma cancers</b><br><b>Dr Mai-Britt Zocca</b> , CEO and Founder, <b>IO Biotech Aps</b>                                                            |
| 13:00 | <b>Universal pandemic and seasonal influenza vaccine design: Directing the antibody repertoire</b>                                                                                         | <b>Using reverse genetics systems to engineer protective vaccine candidates for SARS-CoV and MERS-CoV vaccine design</b><br><b>Prof Luis Enjuanes</b> , Research Professor and Coronavirus Laboratory Head, <b>CNB-CSIC</b> |

13:15 Networking Lunch & Poster Session

|       | RSV VACCINES                                                                                                                                                                                     | CANCER AND IMMUNOTHERAPY VACCINES                                                                                                                                                               | PLATFORM TECHNOLOGIES TO EMERGING PATHOGENS                                                                                                                                                                                                        |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 14:45 | <b>Epidemiology and clinical burden of RSV infection in children</b><br><b>Dr Terho Heikkinen</b> , Assistant Professor of Paediatrics, <b>University of Turku and Turku University Hospital</b> | <b>Optimising HPV vaccine: Combinational trials with checkpoint inhibitors</b><br><b>Willem-Jan Krebber</b> , Director Operations, <b>ISA pharmaceuticals</b>                                   | <b>Preventing the pandemic potential of MERS-CoV: Updates on research and clinical development</b><br><b>In-Kyu Yoon</b> , Deputy Director General of Science, <b>International Vaccine Institute (IVI)</b>                                        |
| 15:15 | <b>Passive and active RSV vaccination for the young and old</b><br><b>Dr Mark Esser</b> , Director, Translational Medicine, Infectious Diseases & Vaccines, <b>Medimmune</b>                     | <b>Safety, immunogenicity and MOA of a novel HPV-cancer immunotherapy: Results of a phase 1 human clinical trial</b><br><b>Dr Frank Bedu-Addo</b> , President and CEO, <b>PDS Biotechnology</b> | <b>Scientific update and global progression of a dengue vaccine reaching endangered populations</b><br><b>Dr Nicholas Jackson</b> , Vice President, Global Head of Research, <b>Sanofi Pasteur</b>                                                 |
| 15:45 | <b>Maternal and paediatric RSV programs in Phase I/II</b>                                                                                                                                        | <b>Updated clinical progress on Amgen's oncolytic virus-based immunotherapy T-VEC against melanoma</b>                                                                                          | <b>Microcrystalline tyrosine (MCT) in combination with novel virus like particles (VLP) for the development of a vaccine against malaria</b><br><b>Dr Matthew Heath</b> , Manager, Scientific & Technical Affairs, <b>Bencard Adjuvant Systems</b> |
| 16:00 |                                                                                                                                                                                                  |                                                                                                                                                                                                 | <b>The journey to producing an effective malaria vaccine – what's next?</b>                                                                                                                                                                        |

16:15 Networking Break

|       |                                                                                                                                                  |                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                   |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 16:45 | <b>The RSV nanoparticle vaccine, two ph3 trial updates on elderly, infant and maternal immunisation</b>                                          | <b>Oncolytic viruses as immunotherapy – from Laboratory to Clinic</b><br><b>Professor Alan Melcher</b> , Professor of Clinical Oncology and Biotherapy, <b>Leeds Institute of Cancer &amp; Pathology</b> | <b>Advancing HIV vaccines from bench to clinic</b><br><b>Dr Antu K. Dey</b> , Senior Director, Research & Development, <b>International AIDS Vaccine Initiative</b>                                                                                               |
| 17:15 | <b>Scientific challenges and results on developing a new pertussis vaccine</b><br><b>Dr Rino Rappuoli</b> , Chief Scientist, <b>GSK Vaccines</b> | <b>Optimizing the therapeutic benefit of checkpoint inhibitors and broadening the potential of immunotherapy</b>                                                                                         | <b>Funding status and opportunities for vaccines against emerging diseases</b><br><b>Dr Cristina Cassetti</b> , Deputy Chief, Virology Branch Division of Microbiology and Infectious Diseases, <b>National Institute of Allergy and Infectious Diseases, NIH</b> |

17:45 Chair closing remarks of day one followed by drinks reception



## PLENARY SESSION

9:00

**Chair's opening remarks**

9:10

### Impact of new vaccine technology across the value chain: The difficulty and the necessity to innovate

- The increasing need to protect against infectious diseases, cancer and other chronic conditions
- A revolution in the vaccine field: Recent advances in immunology, structural biology, synthetic biology and genomics
- Overcoming challenges in controversies in the safety of adjuvants, increasing regulatory complexity, the inadequate methods used to assess the value of novel vaccines, and the resulting industry alienation from future investment



**Dr Rino Rappuoli**, Chief Scientist, **GSK Vaccines**

9:40

### Joint discussions: Vaccines manufacturing complexity and regulatory hurdles

- WHO update on new Post Approval Change guidelines
- Industry comment on the new for regulatory convergence
- Authority viewpoint on vaccines complexity



**Dr Stephen Cook**, VP, Vaccine Global Regulatory Affairs; Head of International Region (EMAP / Japan / WHO), **GSK Vaccines** & representing **IFPMA**



**Dr DianLiang Lei**, Scientist, Department of Essential Medicines and Health Products (EMP), **World Health Organization (WHO)**



**Dr Heidi Meyer**, Deputy Head of the Department of Viral vaccines, **Paul-Ehrlich-Institut, Germany**



**Dr Suresh Jadhav**, Executive Director, **Serum Institute of India**

10:40

Morning break

11:40

## INTERACTIVE ROUNDTABLES

Choose two roundtable session and explore a range of topical issues that can be discussed with other thought leaders at a more interactive basis. Go to the end of the agenda for more information:

To lead a table or for more information on other topics contact the Project Manager **Wing-yun Cheung** on [wing-yun.cheung@terrapinn.com](mailto:wing-yun.cheung@terrapinn.com)

13:10

Networking Lunch & Poster Session

14:40

### NEW VACCINE TECHNOLOGY & DISCOVERY

#### Chair's opening remarks

**Dr Jeffrey Almond**, Former Vice President Discovery Research and Development, Sanofi and Visiting Professor, **University of Oxford**

### PRE-CLINICAL TO CLINICAL DEVELOPMENT

#### Chair's opening remarks

### VACCINE BIOPROCESSING

#### Chair's opening remarks

**Dr Antu Dey**, Senior Director, Research & Development, **International AIDS Vaccine Initiative (IAVI)**

14:45

### SHOWCASING NEW TECHNOLOGY

#### Technology Showcase 1

Next Generation Conjugate Vaccines: How can cell-free protein synthesis permit high-fidelity conjugation to enhance immunogenicity & expand serotype coverage?

**Grant E. Pickering**, President & CEO, **SutroVax Inc.**

### PREDICTING CLINICAL OUTCOME

#### Pre-clinical to clinical vaccine interphase R&D interphase

**Dr Miles Carroll**, Deputy Director, Head of Research, **Department of Health**

### FORMULATION AND BIOPROCESSING

#### Physio/chemical analysis to solve the stabilisation challenges in glycoconjugate vaccines

**Dr Michele Pallaoro**, Head, Vaccines & Diagnostics, **GSK Vaccines**

|       |                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                          |                                                                                                                                                                             |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15:00 | <b>Technology Showcase 2</b><br>Introducing a Multiple Antigen Presenting System – Enabling high affinity binding of protective polysaccharides and proteins in a single vaccine<br><b>Dr Richard Malley</b> , Scientific Founder & CSO, <b>Affinivax</b> |                                                                                                                                                                                                                          |                                                                                                                                                                             |
| 15:15 | <b>Technology Showcase 3</b><br>The ability of modified mRNA to express viral antigens in vivo and to induce robust immune responses<br><b>Dr Giuseppe Ciarrella</b> , Chief Scientific Officer, Valera, <b>A Moderna Venture</b>                         | <b>An integrated biomarker and diagnostic plan for RSV epidemiology studies and vaccine clinical trials</b><br><b>Dr Mark Esser</b> , Director, Translational Medicine, Infectious Diseases & Vaccines, <b>Medimmune</b> | <b>Stabilizing formulations for recombinant viruses</b>                                                                                                                     |
| 15:30 | <b>Technology Showcase 4</b><br>Nanoparticle RNA vaccines for potent cancer immunotherapy<br><b>Dr Mustafa Diken</b> , Deputy Vice President of Immunotherapies and Preclinical Research, <b>Biontech RNA Pharmaceuticals GmbH</b>                        |                                                                                                                                                                                                                          |                                                                                                                                                                             |
| 15:45 | <b>Technology Showcase 5</b><br>Session to be confirmed<br><b>Dr Eva Gelius</b> , Team Leader, R&D, <b>Mabtech</b>                                                                                                                                        | <b>Vaccines and Viral Challenge Agents – What's the difference?</b><br><b>Dr Adrian Wildfire</b> , Project Director - Infectious Diseases & Viral Challenge Unit, <b>SGS Life Sciences</b>                               | <b>Implementing predictive modelling to improve control on process robustness</b><br><b>Senior representative, Batavia Biosciences</b>                                      |
| 16:00 | <b>Technology Showcase 6</b><br>Developing a nanoparticle vaccine system                                                                                                                                                                                  |                                                                                                                                                                                                                          | <b>Virus Counter-based monitoring during production process of viral vaccines</b><br><b>Dr Jens Knauer</b> , IDT Biologika                                                  |
| 16:15 | Networking Break                                                                                                                                                                                                                                          |                                                                                                                                                                                                                          |                                                                                                                                                                             |
| 16:45 | <b>The potential of self-amplifying mRNA vaccines</b><br><b>Dr Jeffrey B. Ulmer</b> , Head, Preclinical R&D US, <b>GSK Vaccines</b>                                                                                                                       | <b>Human viral challenge studies: Accelerating drug and vaccine development</b><br><b>Senior representative, hVIVO</b>                                                                                                   | <b>Definition of formulation strategy for vaccines</b>                                                                                                                      |
| 17:15 | <b>Using VLP technology to develop a Norovirus vaccine candidate</b>                                                                                                                                                                                      | <b>Correlates of protection: The ability to establish what they are and what they can test</b>                                                                                                                           | <b>Lessons learnt on producing and purifying over thirty different VLP's for a universal influenza vaccine</b><br><b>Dr Antonio Roldao</b> , Senior Researcher, <b>IBET</b> |
| 17:45 |                                                                                                                                                                                                                                                           | <b>Key factors for success in publishing vaccine clinical trials</b><br><b>Anne Hepburn</b> , Director, Scientific Writing and Regulatory Affairs, <b>4Clinics</b>                                                       | <b>Building a reliable fill-finish infrastructure to support pre-clinical batches and final finished product/dosage forms</b>                                               |
| 18:15 | Chair's closing remarks and close of day two followed by Meet & Greet with key speakers                                                                                                                                                                   |                                                                                                                                                                                                                          |                                                                                                                                                                             |



|       | CLINICAL DEVELOPMENT IN VACCINES TO ADDRESS AMR                                                                                                                                                                                                        | VACCINE DELIVERY                                                                                                                                                                                                                                                                                   | MANUFACTURING                                                                                                                                                                                                                             |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 9:05  | <b>Chair's opening remarks</b><br><b>Dr Jan T Poolman</b> , Head Bacterial Vaccine Discovery and Early Development, <b>Janssen</b>                                                                                                                     | <b>Chair's opening remarks</b><br><b>Dr Greg Widmyer</b> , Deputy Director for Vaccine Introduction and Market Dynamics, <b>The Bill &amp; Melinda Gates Foundation</b>                                                                                                                            | <b>Chair's opening remarks</b><br><b>Dr Antu K. Dey</b> , Senior Director, Research & Development, <b>International AIDS Vaccine Initiative</b>                                                                                           |
| 9:10  | <b>Epidemiology: How big is the problem of AMR?</b>                                                                                                                                                                                                    | <b>Vaccine delivery technologies that provide mucosal and systemic immunity</b><br><b>Dr Derek O'Hagan</b> , Global Head of Vaccine Chemistry and Formulation Research, <b>GSK</b>                                                                                                                 | <b>To what extent are disposable technologies a better choice for rapid and effective delivery of vaccines</b><br><b>Senior representative, Pall</b>                                                                                      |
| 9:40  | <b>Bacterial paediatric vaccine overview: Using bacterial vaccines for AMR vaccines</b><br><b>Dr Jan T Poolman</b> , Head Bacterial Vaccine Discovery and Early Development, <b>Janssen</b>                                                            | <b>How physico-chemical properties of liposomes, emulsions, antigens and different routes of delivery can influence the immunological outcome</b><br><b>Dr Dennis Christensen</b> , Head of section, Vaccine Research & Development , Infectious Disease Immunology, <b>Statens Serum Institut</b> | <b>Bioreactor needs for the developing world: Vaccine self-sufficiency and pandemic outbreaks</b><br><b>XL Lin</b> , Founder, President & CEO, <b>VacciXcell a member of Esco Group of companies</b>                                      |
| 10:20 | <b>Recent progress on the TB vaccine VPM 1002, which is currently assessed in a phase II trial in HIV exposed neonates</b><br><b>Prof Stefan Kaufmann</b> , Founding Director and Managing Director, <b>Max Planck Institute for Infection Biology</b> | <b>Developing a single-use fit for all intradermal delivery</b><br><b>Dr Yotam Levin</b> , CEO, <b>NanoPass Technologies</b>                                                                                                                                                                       | <b>Accelerating the development and manufacturing of Vaccines in critical situations: Case studies &amp; perspectives</b><br><b>Dr Anissa Boumlic-Courtade</b> , Europe Vaccine Market lead Life Science, Process Solutions, <b>Merck</b> |
| 10:40 | Networking Break                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                           |
| 11:30 | <b>Extraintestinal pathogenic Escherichia coli, a common human pathogen: Challenges for vaccine development and progress in the field</b><br><b>Dr Peter Hermans</b> , Senior Scientific Director, <b>Janssen</b>                                      | <b>Polyphosphazenes - vaccine delivery vehicles or immunostimulants?</b><br><b>Dr Alexander K. Andrianov</b> , Professor, Institute for Bioscience and biotechnology Research, <b>University of Maryland</b>                                                                                       | <b>Overview of QbD application to vaccines development, with practical examples</b><br><b>Dr Cristiana Campa</b> , Head, Quality by Design Integration, <b>GSK Vaccines</b>                                                               |
| 12:00 | <b>Clinical update and vaccine progression in Staph aureus</b><br><b>Dr Annaliesa Anderson</b> , Vice President and CSO Bacterial Vaccines, <b>Pfizer</b>                                                                                              | <b>What are the analytical challenges between traditional freeze dry formulations and patches?</b>                                                                                                                                                                                                 | <b>Executing comparability protocols: How can specific manufacturing changes effect the safety or effectiveness of vaccine?</b><br><b>Dr Kuldip Sra</b> , Associate Director/Principal Scientist, <b>Astra Zeneca</b>                     |
| 12:30 | Networking Lunch                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                           |



## PLENARY SESSION

13:30

Chair's opening remarks

13:35

### Justifying maternal immunization: Where are we with development of vaccines that affect maternal and infant health?

- Policy, products and regulatory Requirements
- Developments and results from clinical trials and vaccination rates
- Ethical considerations and business sustainability

**Thomas Breuer**, SVP & Chief Medical Officer, **GSK Vaccines**



14:05

### Interactive discussion: Is the eradication of Measles and containment of the virus possible? A scientific and political matter

- Progress toward measles elimination
- Different aspects of global policy and challenges to measles vaccination
- What happens after eradication?
- Will similar viruses take over?
- Preparation strategies



**Prof Albert Osterhaus**, Director Research Center for Emerging Infections and Zoonoses (RIZ), **University of Veterinary Medicine Hannover**



**Dr James L. Goodson**, Senior Measles Scientist, Accelerated Disease Control and VPD Surveillance Branch, Global Immunization Division, **Center for Global Health, CDC**

14:50

### Interactive discussion: Access to vaccines - Ensuring resilience of high quality vaccine supply

- What are the key long term risks to resilience of vaccine supply
- How should manufacturers, regulators and government work together to build resilience into the global supply of high quality vaccines?
- How might new production technologies and regulatory approaches be harnessed to dealing with fluctuating demand and generally increase resilience?



**Prof Dr Stephen Inglis**, Former Director, **NIBSC**



**Heather Deehan**, Chief, Vaccine Centre, **UNICEF Supply Division**



**Dr Suresh Jadhav**, Executive Director, **Serum Institute of India**



**Thomas Breuer**, SVP & Chief Medical Officer, **GSK Vaccines**



**Dr Anders Vinther**, Chief Quality Officer, **Sanofi Pasteur**

15:50

Chair's closing remarks and close of Congress



## HOW TO CHOOSE WHICH PLATFORM IS MOST SUITABLE TO DEVELOP A NEW VACCINE FOR AN EMERGING DISEASE

14:45

Welcoming address

**New vaccines are all moving away from traditional vaccine approaches so how do we choose one platform over another?**

What are the range of viruses that we need to be ready for? The threat of the Zika virus



**Prof Albert Osterhaus**, Director Research Center for Emerging Infections and Zoonoses (RIZ), **University of Veterinary Medicine Hannover**

14:50

**Review of different viral and bacterial vector delivery systems**



**Dr Jean-Christophe Audonnet**, ZAPI Project Coordinator, **Meriel**



**Dr Edmond Jolivet**, Head of Molecular Bacteriology laboratory, **Meriel**

**The success of DNA vaccines to the animal health arena**

**How far are we from commercializing nanoparticle technology?**

**Pox virus based platforms**

*More speakers to be announced shortly*

16:15

Networking break

16:45

### ROUND TABLE DISCUSSIONS TO DISCUSS PROS AND CONS OF SELECTED PLATFORMS

- How do we ensure that these technologies make it to the market?
- Considerations to regulatory hurdles, scalability, manufacture and cost

17:15

Presentation of conclusions by discussion leaders

17:45

End of Workshop and Networking Drinks Reception



9:00

Chair's opening remarks

## BRINGING TOGETHER HUMAN AND ANIMAL VACCINES

9:10

### Where is the veterinary vaccines industry heading?

- The journey of developing Bovela
- Consolidation of the industry
- Threat of emerging and infectious diseases to animal and human health

**Dr Randolph Seidler**, Managing Director, Global Head of R&D Animal Health, **Boehringer Ingelheim Veterinary Research Center**



9:40

### One Health: Efforts made around emerging and food borne pathogens

- What reasonable guidelines should we all follow?
- Blurring the lines between human and animal health
- The dramatic food safety potential in using vaccines

**Dr Arvind Mahajan**, Director Research and Development, **Elanco**



10:10

### Developing clinical model to support vaccines research and development

- Clinical models that can test vaccine efficacy in different situations, examples in swine
- Gaining better insights from animals models that could be applicable to human vaccine development like MERS

**Dr Joaquim Segalés**, Director, **Centre de Recerca en Sanitat Animal (CRESA)**



10:40

Networking break

11:40

## INTERACTIVE ROUNDTABLES

Choose two roundtable session and explore a range of topical issues that can be discussed with other thought leaders at a more interactive basis. Go to the end of the agenda for more information:

To lead a table or for more information on other topics contact the Project Manager **Wing-yun Cheung** on [wing-yun.cheung@terrapinn.com](mailto:wing-yun.cheung@terrapinn.com)

13:10

Networking Lunch & Poster Session

14:40

### Bridging the gap between animal and human adjuvanted vaccines

- How can we extrapolate the use of adjuvants in animal and human vaccines to benefit all species
- Measuring efficacy, toxicity and correlates of protection

**Dr Nathalie Garcon**, CSO/CTO, **Bioaster**



## INCORPORATING NOVEL VACCINOLOGY APPROACHES

15:15

### Presenting a novel live bacterial adjuvanted vaccine

- R&D challenges in developing a live vaccine
- Identifying the right adjuvants and rationale in vaccine design

**Dr Edmond Jolivet**, Head of Molecular Bacteriology laboratory, **Meriel**



15:45

### Reaching the limits of the baculovirus vector technologies for vaccine production

- A disruptive cell line independent baculovirus vector technology to produce vaccines
- Record production yields in a baculovirus technology, up to grams per liter of extract
- Expression of fully functional complex proteins forming VLP
- Significant cost reductions in the baculovirus technology both in fixed investments and cost of goods
- High ratios of success in "difficult to express" proteins

**Dr Romy M. Dalton**, Chief Operations Officer, **Algenex**



16:15

Afternoon break

16:45

### When is reverse vaccinology appropriate to use? Future developments of efficacious vaccines

- R&D challenges in developing a live vaccine
- Identifying the right adjuvants and rationale in vaccine design

17:15

### Technologies to facilitate a rapid vaccine response to newly emerging pathogens

- Identification of protective antigens
- Novel adjuvants to increase potency and breadth
- Rapid response to newly emerging pathogens

**Dr Jeffrey B. Ulmer**, Head, Preclinical R&D US, **GSK Vaccines**



17:45

### The role of novel diagnostic methods in protecting both animals and humans

- Using high throughput technologies and marker vaccines to differentiate between vaccinated and infected animals
- Understanding the pathogenesis of infectious diseases like Avian Influenza virus (AIV), Bluetongue virus (BTV) and Schmallenberg virus (SBV) to prevent outbreaks

18:15

Chair's closing remarks and close of day two followed by **Meet & Greet with key speakers**

9:00

Chair's opening remarks

## EMERGING & RE-EMERGING DISEASES

9:10

### One step closer to developing an effective MERS-CoV vaccine: New camel data

- An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
- Illustrating how a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels
- Significantly reducing excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge

**Prof Albert Osterhaus**, Director Research Center for Emerging Infections and Zoonoses (RIZ), **University of Veterinary Medicine Hannover, Foundation**



9:40

### Intervention strategies to support the global control and eradication of foot-and-mouth disease virus

- How can the industry work together to contribute in a fast response and speed to the market in case of an emerging infectious

10:10

### Influenza vaccine candidates based on the pox viral vector MVA

**Professor Guus Rimmelzwaan**, Viroscience lab, **Erasmus MC**



10:40

Networking break

11:30

### A one health approach to developing vaccines against bovine tuberculosis

- Using animals models that give more clinically meaningful information to human vaccine development, bovine TB
- Eradication at the source for human and animal protection
- Understanding the epidemiological status – how could the movement of people from the Middle East to western Europe (or other external factors) increase the risk of infection?

**Dr Glyn Hewinson**, Chief Scientist, Lead in TB, **Animal & Plant Health Agency, UK**



12:00

### Vaccines for the developing world: Accessibility and affordability

- New vaccine formulations for developing world livestock
- Responding to emerging infectious disease outbreaks – Rift valley fever

**Dr Jeremy Salt**, Senior director R&D, **GALVmed**



12:30

Networking lunch

## THE PATH TO DEVELOPING EFFECTIVE VETERINARY VACCINES

13:30

### Utilizing a fixed-bed bioreactor as a solution to improve manufacturing capacity and cost of goods for veterinary vaccines

**Senior representative, Pall - Session to be finalised**



14:00

### The challenge of Leishmania vaccine development

- After 20 years, highlighting the development, registration or clinical challenges of developing a neglected disease vaccine

**Dr Mercedes Fabra**, Project leader, Immunology and Vaccines for Global Health, **Laboratorios LETI, S.L.**



14:30

### Easing vaccination programs through combination

- Combined vaccines and separate vaccines that can combined during application (compatibility)
- Reducing number of applications to improve animal welfare

**Dr Rik Koopman**, Global Technical Director, Global Poultry Business Unit, **MSD Animal Health**



15:00

### Purification strategies that supports greater consistency and higher quality veterinary vaccines

- Maintaining efficient control of veterinary diseases, while allowing production to remain economically competitive
- Membrane-based clarification and concentration techniques

15:30

Chair's closing remarks and close of congress



# Interactive Roundtables

Choose your  
roundtable session  
and explore a range  
of topical issues that  
can be discussed with  
other thought leaders  
at a more  
interactive basis.

Adjuvants and technology  
advancements  
driving vaccine R&D

Promoting a one health  
research ethos by bringing  
veterinary and medical  
scientists together

**Prof Albert Osterhaus**, Director  
Research Center for Emerging  
Infections and Zoonoses (RIZ),  
**University of Veterinary  
Medicine Hannover**

Latest  
innovations and  
remaining bottlenecks  
in process development of  
viral vaccines

**Miriam Monge**, Director of Process  
development & bioprocess Platform  
Marketing team  
**Amélie Boulais**, Vaccines platform  
marketing manager, **Sartorius  
Stedim Biotech**

Do we need correlates of  
protection for an effective  
vaccine?

**Dr Adrian Wildfire**,  
Project Director - Infectious Diseases  
& Viral Challenge Unit,  
**SGS Life Sciences**

What's the global  
strategy in responding to  
infectious diseases?

Combined efforts and differences  
between Europe and the US

From surrogate markers  
to predictive biomarkers  
of vaccine efficacy: How  
realistic is it to enhance the  
blood markers beyond serum  
antibody?

**Dr Ali M. Harandi**, Lab head,  
Dpt of Microbiology & Immunology,  
**University of Gothenburg**

Developing improved  
analytical testing for next-  
generation vaccines

**Dr Cristiana Campa**,  
Head, Quality by  
Design Integration,  
**GSK Vaccines**

Use of design of  
experimentation in the  
development of vaccines

**Dr Kuldip Sra**,  
Associate Director/Principal Scientist,  
**AstraZeneca**

Vaccine delivery:  
How to increase  
efficacy of vaccines, and  
the challenges from moving  
to therapeutic vaccines versus  
prophylactic

**Kirsty Gapp**,  
M.T.S Business Development  
Manager,  
**3M Healthcare**

Vaccines, commensals,  
and the microbiome:  
Tailoring an immune  
response to maintain a  
beneficial equilibrium

**Dr Blaine Pfeifer**, Associate Professor,  
Chemical and Biological Engineering  
Department, **State University of  
New York at Buffalo**

Zika virus:  
Challenges for medical  
countermeasure development

**Prof Leda Castilho**, Professor,  
**Universidade Federal do Rio de  
Janeiro**

Pre-clinical biomarkers  
of safety and efficacy in vaccine  
design and development

To lead a table or for more information on other topics contact the  
Project Manager Contact **Wing-yun Cheung** on +44 (0)20 7092 1172  
or [wing-yun.cheung@terrapinn.com](mailto:wing-yun.cheung@terrapinn.com)

# 7

## Reasons to attend

1

Understand how the industry is characterising the immune response during infection, disease and vaccination with new systems and high-throughput technologies at the **Immune Profiling World Congress** – the only European event focused solely on immune profiling to aid therapeutic design and treatment strategies for infectious and non-infectious diseases.

2

Hear from senior big pharma, biotech and leading academic experts including **Prof Stefan Kaufmann**, Founding Director and Managing Director, **Max Planck Institute for Infection Biology**, **Dr Roy Baynes**, Senior Vice President Global Clinical Development, **MSD** and **Prof Zelig Eshhar**, Professor, Chemical & Cellular Immunology, **Weizmann Institute of Science**.

3

Want to know who else are already committed to the event? Organisations include: **HIVACAT, Aduro Biotech, Tel Aviv University, Adaptimmune, INSERM, Medimmune, University of Gothenburg, Precision Biologics, The Center for Infectious Disease Research, MSD, Max Planck Institute** and many more!

4

Co-located with the **17th World Vaccine Congress**, gain a wider understanding of how characterising the immune system can aid with **vaccine design**. Benefit from having access to additional sessions of interest in **vaccine R&D, pre-clinical development** and **new platform technologies**.

5

No matter what part of the immune system you're interested in, we will extensively cover methods of characterisation, identifying **biomarkers** and **surrogate markers, immunosequencing, high throughput analysis** and interpretation of **omics data** and **immune-oncology**.

6

Excited about the recent **immune-oncology** developments? If you are interested in check **point inhibitors, neoantigens, adoptive T-cells therapies, CAR T-cells, oncolytic viruses** or combinational methods, look no further. We have all the most innovative immunotherapy approaches covered.

7

There are fantastic networking opportunities, with two days' worth of content, extended breaks, a drinks receptions and a co-located event, you will have even more time to meet cross sector contacts with over **450 attendees**.

Save money and book early at [terrapiinn.com/immune16](https://terrapiinn.com/immune16)

"A 'never miss' conference on my annual list of key scientific conferences. It is a unique meeting where scientists, biotech and pharma representatives, and business leaders discuss and review critical scientific advances, and professionally network."

**Dr Gregory A. Poland**  
Mayo Clinic



# How will our sponsors & exhibitors benefit?

Over the course of the 2 day meeting in Barcelona all the sponsors and exhibitors will benefit from **direct F2F access with over 400 delegates**, where in total there will be over **8 hours of networking sessions** taking place. Different levels of partner involvement and activities offer the following:



## PRESENTATIONS

High level sponsors are able to give full speaker case study presentations directly to potential and existing clients reinforcing their credibility and demonstrating thought leadership on specific topic areas.



## EXHIBITION

With over 30 exhibitors in total in 2016, they all have a unique opportunity to put their business products and services in front of potential buyers looking to source the latest technologies in the vaccine industry. This enables our clients to generate a high level of sales leads and form strong new relationships. All the complimentary buffet lunches and refreshments take place in this room, ensuring potential clients are in touching distance at all times when not in the conference.



## BRAND AND POSITIONING

Through the associated company logo visibility on our banners and event marketing information on-site, the sponsors and exhibitors in Barcelona will be able to build their brand and positioning within the vaccine industry. This in turn will help them be seen as a leading solutions and service provider to new and existing customers, as well aligning themselves with industry bellwethers.



## DRINKS RECEPTION

The drinks networking receptions at the end of the day will offer everyone the chance to unwind and relax in a more informal setting, developing further the business relationships that are initiated during the day.



## NETWORKING MANAGER

As a high level sponsor there is the opportunity to have your own private networking manager for the 2 days, who will work closely with you to facilitate and arrange 1-2-1 business meetings at the event. They will send out the attendee list approx. 4 weeks prior for the sponsor to choose pre-qualified targeted clients, and we will then assist pre-event and on-site for your team to have those meetings in your own reserved private meeting space.



## JUBLIA NETWORKING SYSTEM

Jublia is our dedicated online networking tool used at the event by all the attendees, ensuring everyone focuses their time in valuable conversations and meetings with the right people for their business. It will be used at the event to ensure delegates manage their time onsite efficiently, can find attendees who share the same interests, can search for individuals by industry, company or name, can send and receive emails to the people they'd like to get in contact with, and set up their onsite meetings. Delegates are able to target and arrange to meet everyone they want to before the event begins via the on-line portal.



**Want to get involved? Contact Jade Liddell on +44 (0)20 7092 1131 or [jade.liddell@terrapinn.com](mailto:jade.liddell@terrapinn.com)**

# 2016 Floor plan

## WHO WILL YOU MEET?


- Innovators
- Disruptors
- Decision-Makers
- Influencers
- End-users from large and mid-cap vaccine manufacturers
- SME Biotech
- Academic
- Research Institutes
- Government Bodies
- Regulatory Boards
- Industry Solution Providers

## THIS IS A PRIME OPPORTUNITY FOR:

- CROs
- CMOs
- Platform Technology Providers
- Fill / Finish
- Finished Dosage
- Platform Technology Providers
- Drug Delivery Providers
- Drug Diagnostic Providers
- Medical Device Manufacturers
- OEM /Equipment Providers
- Logistics Companies

## SPONSORSHIP OPPORTUNITIES INCLUDE:

- Programme presence – from plenary to track sessions
- Exhibition
- Drinks Reception Sponsor
- Sponsor of the Scientific Poster Session
- Networking Break Sponsor
- Lanyard Sponsor
- Wi-Fi Sponsor
- Show Guide Sponsor



# Reserve your place today

The earlier you book, the more you'll save.

[terrapinn.com/immune16](http://terrapinn.com/immune16)

| PACKAGES                                                 | BOOK BEFORE<br>1 APR       | BOOK BEFORE<br>27 MAY     | BOOK BEFORE<br>22 JUL     | BOOK BEFORE<br>12 AUG     | BOOK BEFORE<br>2 SEP      | BOOK BEFORE<br>23 SEP     | FULL PRICE |
|----------------------------------------------------------|----------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------|
| Standard Package                                         | €1550<br><b>SAVE €1035</b> | €1810<br><b>SAVE €775</b> | €2055<br><b>SAVE €530</b> | €2190<br><b>SAVE €395</b> | €2320<br><b>SAVE €265</b> | €2450<br><b>SAVE €135</b> | € 2585     |
| Academic & Regulatory Package                            | €775<br><b>SAVE €520</b>   | €905<br><b>SAVE €390</b>  | €1030<br><b>SAVE €265</b> | €1095<br><b>SAVE €200</b> | €1160<br><b>SAVE €135</b> | €1225<br><b>SAVE €70</b>  | € 1295     |
| Standard Package group booking 3-5 people                | €1395                      | €1630                     | €1850                     | €1970                     | €2090                     | €2205                     | €2325      |
| Academic & Regulatory group booking 3-5 people           | €700                       | €815                      | €925                      | €985                      | €1045                     | €1105                     | €1165      |
| Display a Scientific Poster - add on to attendee package | € 50                       |                           |                           |                           |                           |                           |            |

## BRING YOUR TEAM

With three days packed full of great content and networking opportunities, you can't possibly cover it all alone! Bring your team and get an extra discount.

Call **+44 (0) 207 092 1210**

## MEDIA PARTNERS



# 2016 Sponsors and Exhibitors

## GOLD SPONSORS



## BRONZE SPONSORS



## SHOWCASE SPONSORS



## EXHIBITORS



To create a bespoke package, contact **Jade Liddell** on  
+44 (0)20 7092 1131 or [jade.liddell@terrapinn.com](mailto:jade.liddell@terrapinn.com)